In this article, we will take a look at the 5 Most Profitable Small Cap Stocks to Buy. For a deeper discussion and an extended list, please see the 10 Most Profitable Small Cap Stocks to Buy.
5. Idaho Strategic Resources, Inc. (NYSE:IDR)
Net Profit Margin: 43.33%
Operating Margin: 52.35%
Idaho Strategic Resources, Inc. (NYSE:IDR) is among the Most Profitable Stocks.
On May 21, 2026, Idaho Strategic Resources, Inc. (NYSE:IDR) said a project proposal submitted to the US Department of Energy under Funding Opportunity 3105 was selected for funding. A May 19 DOE announcement was a “welcomed achievement” following its December 2023 submission, as per the firm. The company said the project brings together Idaho stakeholders to move forward with the exploration and extraction of rare earth elements for potential marketing.
On May 14, 2026, Idaho Strategic Resources, Inc. (NYSE:IDR) reported Q1 EPS of $0.40 as compared to $0.12 last year, while reporting revenue of $14.48 million compared with $7.28 million. The corporation said ounces produced rose 11.52% year over year to 3,234 from 2,900.
CEO John Swallow said “record first quarter results” showed execution with increased production and expanded drilling programs supported the plan. The CEO also noted new permits and acquisitions that add copper and silver exposure and long-term exploration targets.
Idaho Strategic Resources, Inc. (NYSE:IDR) is involved in the exploration and development of gold, silver, and base metal resources. It has mineral properties, including the Golden Chest Mine, Murray Gold Belt, Butte Highlands, and Central Idaho.
4. CorMedix Inc. (NASDAQ:CRMD)
Net Profit Margin: 45.25%
Operating Margin: 49.96%
On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 million. The firm said DefenCath contributed $97.5 million in revenue with higher outpatient dialysis utilization and a $9.0 million favorable estimate change. The acquired Melinta portfolio added $29.9 million.
The company raised its 2026 guidance, projecting revenue between $325 million and $345 million and adjusted EBITDA to $115 million-$135 million. The corporation reported cash and short-term investments of $178.1 million as of March 31, 2026.
Chairman and CEO Joseph Todisco said CorMedix entered the year with “strong momentum” and that DefenCath “continues to exceed expectations” despite pending TDAPA expiration. He also noted progress in late-stage programs, including REZZAYO, with the company preparing an FDA submission in the second half of 2026. It targets a potential expanded launch in 2027.
CorMedix Inc. (NASDAQ:CRMD) is a pharmaceutical and medical device firm that makes and markets therapeutic solutions for the prevention and treatment of diseases and conditions.
3. Global Ship Lease, Inc. (NYSE:GSL)
Net Profit Margin: 51.11%
Operating Margin: 50.78%
On June 5, 2026, Global Ship Lease, Inc. (NYSE:GSL) agreed to newbuilding contracts for 10 mid-size, ultra high reefer containerships. It is valued at about $917 million, with deliveries scheduled between Q4 2028 and Q1 2030. The company said the vessels carry multi-year charters averaging 6.7 years, expected to have around $665 million in aggregate adjusted EBITDA.
On May 22, 2026, Global Ship Lease, Inc. (NYSE:GSL) reported Q1 results with revenue of $198.1 million and net income of $91.4 million, or $2.54 per share. It also had an adjusted EBITDA of $133.2 million. The firm announced $86.1 million in contracted revenues, bringing total contracted revenue to $2.05 billion with a 2.6-year weighted duration.
Executive Chairman George Youroukos said the company achieved “100% coverage for 2026 and 86% for 2027,” with stronger demand and rising bunker costs, tightening vessel supply. CEO Thomas Lister added that the firm maintained a “fortress balance sheet.“
Global Ship Lease, Inc. (NYSE:GSL), along with its subsidiaries, owns and leases containerships under fixed-rate charters to container shipping companies globally.
2. Euroseas Ltd. (NASDAQ:ESEA)
Net Profit Margin: 58.31%
Operating Margin: 61.24%
On May 26, 2026, Euroseas Ltd. (NASDAQ:ESEA) announced charter extensions for its “2024-built 1,800 teu feeder containerships, M/V Stephania K and M/V Pepi Star.” It secured new contracts lasting 24 to 26 months at a gross daily rate of $25,500. The company said the charters will begin July 28 and August 19, 2026, continuing directly from the existing agreement.
Chairman and Chief Executive Officer Aristides Pittas said the extensions show “continued demand for tonnage and the underlying strength of the containership charter market.” It pointed out that the modern, fuel-efficient vessels command a premium as disruptions in oil flows through the Strait of Hormuz tighten fuel availability and push costs higher.
Euroseas Ltd. (NASDAQ:ESEA) said the contracts are expected to make around $27 million in EBITDA over the minimum period. The corporation stated that the deals increase charter coverage to roughly 96% for 2026, 86% for 2027, and 48% for 2028.
Euroseas Ltd. (NASDAQ:ESEA) is a holding company that provides ocean-going transportation services. It operates containerships that transport dry and refrigerated containerized cargoes, which primarily include manufactured goods and perishables.
1. Arbutus Biopharma Corporation (NASDAQ:ABUS)
Net Profit Margin: 83%
Operating Margin: 94.41%
On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of the increase in its share of a noncontingent settlement payment through Genevant Sciences.
Arbutus Biopharma Corporation (NASDAQ:ABUS) reported net income of $169.7 million from a $24.5 million loss. The research and development expenses dropped to $4.1 million from $9.0 million with cost reductions and lower trial activity. General and administrative expenses edged higher to $5.9 million due to legal costs, the company added.
Separately, the firm said the US Food and Drug Administration granted Fast Track designation to imdusiran. It noted that the program could speed up development and review timelines.
The corporation ended the quarter with $95.2 million in cash and investments, making its financial position solid, it said.
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical firm. It is involved in developing novel therapeutics that target specific viral diseases.
While we acknowledge the potential of ABUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABUS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
